Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

Otis case study – Nu.Q® Vet Cancer Test

Monday, January 22, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses a case study featuring Otis and the Nu.Q® Vet Cancer Test, presented by Dr. Sue Ettinger. The publication of a related manuscript in a peer-reviewed journal is anticipated to unlock a $5 million milestone payment. Additionally, the first automated version of the test is being developed with Fujifilm Vet Systems.
Price reaction · baseline $19.856 (2024-01-19 close) · hit pre-market · 14 other VNRX headline(s) in the window, move may be shared
day 0 close · peak
+0.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Dr. Sue Ettinger highlights the effectiveness of the Nu.Q® Vet Cancer Test.
  • The upcoming publication in a peer-reviewed journal may lead to a significant milestone payment.
  • The test is being automated in collaboration with Fujifilm Vet Systems.

Full Press Release Details

Watch our short video, featuring Dr. Sue Ettinger, aka Dr. Sue Cancer Vet, as she describes Otis’s story with the Nu.Q ® Vet Cancer Test.

Related Articles

• Press Releases Volition Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats. The publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 million contractual milestone payment
• Press Releases Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems

Volition Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats. The publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 million contractual milestone payment

Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

What is the Nu.Q® Vet Cancer Test?

The Nu.Q® Vet Cancer Test is a diagnostic tool designed to detect cancer in pets.

Who presented Otis's case study?

Dr. Sue Ettinger, known as Dr. Sue Cancer Vet, presented Otis's case study.

What milestone payment is associated with the Nu.Q® test?

The publication of a related manuscript is expected to unlock a $5 million milestone payment.

Who is collaborating on the automated Nu.Q® test?

Volition is collaborating with Fujifilm Vet Systems to automate the Nu.Q® Vet Cancer Test.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare Nu.Q® cancer test Dr. Sue Ettinger Fujifilm Vet Systems
Last updated: Jan 22, 2024

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk